Andrew H. Beck
Andrew H. Beck
Co-Founder and CEO at PathAI
Verified email at - Homepage
Cited by
Cited by
Comprehensive molecular portraits of human breast tumours
Comprehensive molecular portraits of invasive lobular breast cancer
G Ciriello, ML Gatza, AH Beck, MD Wilkerson, SK Rhie, A Pastore, ...
Cell 163 (2), 506-519, 2015
Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer
BE Bejnordi, M Veta, PJ Van Diest, B Van Ginneken, N Karssemeijer, ...
Jama 318 (22), 2199-2210, 2017
Deep learning for identifying metastatic breast cancer
D Wang, A Khosla, R Gargeya, H Irshad, AH Beck
arXiv preprint arXiv:1606.05718, 2016
Systematic analysis of breast cancer morphology uncovers stromal features associated with survival
AH Beck, AR Sangoi, S Leung, RJ Marinelli, TO Nielsen, ...
Science translational medicine 3 (108), 108ra113-108ra113, 2011
Inconsistency in large pharmacogenomic studies
B Haibe-Kains, N El-Hachem, NJ Birkbak, AC Jin, AH Beck, HJWL Aerts, ...
Nature 504 (7480), 389-393, 2013
The Flexner report and the standardization of American medical education
AH Beck
Jama 291 (17), 2139-2140, 2004
Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations
J Guarnerio, M Bezzi, JC Jeong, SV Paffenholz, K Berry, MM Naldini, ...
Cell 165 (2), 289-302, 2016
Genome-wide association studies identify four ER negative–specific breast cancer risk loci
M Garcia-Closas, FJ Couch, S Lindstrom, K Michailidou, MK Schmidt, ...
Nature genetics 45 (4), 392-398, 2013
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity
BC Grabiner, V Nardi, K Birsoy, R Possemato, K Shen, S Sinha, A Jordan, ...
Cancer discovery 4 (5), 554-563, 2014
The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy
R Scherz-Shouval, S Santagata, ML Mendillo, LM Sholl, I Ben-Aharon, ...
Cell 158 (3), 564-578, 2014
Three differentiation states risk-stratify bladder cancer into distinct subtypes
JP Volkmer, D Sahoo, RK Chin, PL Ho, C Tang, AV Kurtova, ...
Proceedings of the National Academy of Sciences 109 (6), 2078-2083, 2012
Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers
AL Brunner, AH Beck, B Edris, RT Sweeney, SX Zhu, R Li, K Montgomery, ...
Genome biology 13 (8), 1-13, 2012
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
JD French, M Ghoussaini, SL Edwards, KB Meyer, K Michailidou, ...
The American Journal of Human Genetics 92 (4), 489-503, 2013
Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function
A Papa, L Wan, M Bonora, L Salmena, MS Song, RM Hobbs, A Lunardi, ...
Cell 157 (3), 595-610, 2014
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
B Edris, K Weiskopf, AK Volkmer, JP Volkmer, SB Willingham, ...
Proceedings of the National Academy of Sciences 109 (17), 6656-6661, 2012
Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence
RK Pai, AH Beck, JA Norton, TA Longacre
The American journal of surgical pathology 33 (10), 1425-1439, 2009
The macrophage colony-stimulating factor 1 response signature in breast carcinoma
AH Beck, I Espinosa, B Edris, R Li, K Montgomery, S Zhu, S Varma, ...
Clinical cancer research 15 (3), 778-787, 2009
Mammographic density and risk of breast cancer by age and tumor characteristics
KA Bertrand, RM Tamimi, CG Scott, MR Jensen, VS Pankratz, D Visscher, ...
Breast Cancer Research 15 (6), 1-13, 2013
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
MM Hefti, R Hu, NW Knoblauch, LC Collins, B Haibe-Kains, RM Tamimi, ...
Breast Cancer Research 15 (4), 1-13, 2013
The system can't perform the operation now. Try again later.
Articles 1–20